Blue Lake Biotechnology

Startup

Blue Lake Biotechnology is a clinical stage company developing intranasal vaccines that harness the full breadth of the immune system to prevent serious infectious diseases and potentially reduce their spread. Our lead vaccine, BLB201, is being developed to protect infants and young children as well as adults from respiratory syncytial virus (RSV), with preliminary data from a Phase 1/2a trial showing that it reduced the rate of symptomatic infection in infants and young children by over 80%.  We use parainfluenza virus 5 (PIV5) as a live vaccine vector, leveraging the long safety record of human exposure to PIV5 through its 50+ year history of use as an intranasal kennel cough vaccine in dogs. Our vaccines have been shown to generate mucosal immunity and CD8+ killer T-cell immunity as well as humoral immunity in clinical studies, and we have animal proof-of-concept for PIV5-based vaccines against 10+ other pathogens, including avian flu (H5N1 and H7N9), seasonal flu, MERS, Ebola, Nipah, and norovirus. We seek partners and investors interested in any of our existing programs or in applying our novel vaccine vector to new pathogens.

website